Perceptive Capital Solutions CORP 8-K filings

Freenome, Inc. (formerly PCSC) filed an amendment to its 8-K to include financial statements and MD&A following its business combination, reporting significant net losses and cash burn.

Freenome's SimpleScreen CRC blood-based screening test for colorectal cancer has received FDA approval, with Abbott set to commercialize it in the U.S.

Perceptive Capital Solutions Corp announced the approval of key proposals at its July 15, 2026, extraordinary general meeting, paving the way for a business combination.

Perceptive Capital Solutions Corp has postponed its extraordinary general meeting to July 15, 2026, to allow for supplemental disclosures regarding its business combination with Freenome Holdings, Inc.

Perceptive Capital Solutions Corp (PCSC) and Freenome Holdings, Inc. announced the SEC has declared their business combination registration statement effective, with a shareholder meeting scheduled for July 9, 2026.

Perceptive Capital Solutions Corp. has extended its deadline to complete an initial business combination by one year, moving it from June 13, 2026, to June 13, 2027, following shareholder approval.

Freenome Holdings, Inc., an early cancer detection company, will merge with Perceptive Capital Solutions Corp (PCSC) to become a publicly listed entity on Nasdaq under the ticker FRNM, supported by a $240 million PIPE investment.

Perceptive Capital Solutions Corp filed an amendment to its initial 8-K report to include a missing signature on the audit report, while also detailing the closing of its IPO and related financial activities.

Perceptive Capital Solutions Corp successfully completed its initial public offering, raising $86.25 million to pursue a business combination.

Perceptive Capital Solutions Corp, a healthcare-focused special purpose acquisition company, has successfully priced its initial public offering at $10.00 per share, raising gross proceeds of $75 million.